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Purpose. To determine whether in vivo proton magnetic resonance spectroscopy at 3T can provide accurate breast lesion
characterization,andtodeterminetheeﬀectofgadoliniumontheresonanceoftCho.Methods.Twenty-fourpositive-mammogram
patients were examined on a 3T MR scanner. 1H-MRS was performed before and after gadolinium administration. tCho peak
was qualitatively evaluated before and after contrast injection. Results. Fourteen out of 27 lesions proved to be malignant after
histopathological diagnosis. Using 1H-MRS, before contrast injection, 6/14 conﬁrmed malignancies and 11/13 benign lesions
were correctly classiﬁed; while, after contrast injection, 11/14 conﬁrmed malignancies and 12/13 benign processes were correctly
classiﬁed. Post gadolinium 1H-MRS proved useful in picking up tCho signal, improving the overall accuracy, sensitivity, and
speciﬁcity by 35%, 83%, and 9%, respectively. Conclusion. 1H-MRS overall accuracy, sensitivity, and speciﬁcity in detecting breast
lesion’s malignancy were increased after gadolinium administration. It is prudent to perform 1H-MRS before contrast injection
in large breast lesions to avoid choline underestimation. In cases of small or non-mass lesions, it is recommended to perform
1H-MRS after contrast injection for better voxel prescription to enable a reliable preoperative diagnosis.
1.Introduction
Conventional breast MRI has shown diagnostic sensitivities
of 94–99% for screening breast lesions, whereas relatively
low speciﬁcities have been reported, resulting in many
unnecessary biopsies of benign lesions [1, 2]. Breast lesion
characterization is based upon the combination of morpho-
logicalfeaturesofthelesionandpatternsofdynamiccontrast
enhancement of gadolinium-based contrast agent. However,
as dynamic contrast-enhanced MR imaging has already
gained acceptance as important breast imaging modality, it
does not always lead to unambiguous diagnosis as their high
sensitivity comes also with low speciﬁcity (53–80%) [3–7].
In addition to morphologic and kinetic analyses, molec-
ular information has been expected to be useful for the diag-
nosis of breast disease. In vivo proton (1H) MR spectroscopy
(MRS) of the breast, which provides molecular information
obtained in a noninvasive manner, has shown that choline-
containing compounds can be detected in most breast
cancers [1, 2], whereas choline is generally not detectable in
normal breast tissue.
The quality of 1H-MRS measurements-aﬀecting Cho
detectability depends on a variety of factors including MR
sensitivity, spectral resolution, and voxel localization per-
formance. Sensitivity increases linearly with voxel volume,
increasing magnetic (B0) ﬁeld strength, and the square root
of the number of averages acquired in the MRS sequence.
Spectral resolution is increased by higher B0 ﬁeld strengths
and by optimizing B0 shimming to improve MRI ﬁeld
homogeneity over a given region of interest (ROI) of a breast
tumor.
Finally, eﬀective placement of the voxel requires high-
quality MR images to identify the breast lesion. The most
straightforward use of the increased SNR in 3T MR imaging2 The Scientiﬁc World Journal
is for smaller pixel sizes (improved spatial resolution) and
thinner slices or a combination of both. Thus, in breast
spectroscopy, this gain in spatial resolution can be translated
into a better adjustment of the size and position of the voxel
on the lesion while minimizing adjacent ﬁbrogranular or
adipose tissue.
The aim of the most 1H-MRS studies reported to date
has been to determine if the detectability of Cho resonance is
indicative of malignancy. The working assumption for these
studies is that higher tCho concentrations in malignancies
make it easier to detect a Cho resonance. However, not
all lesions are suﬃciently large in size or may have non
mass morphology limiting the diagnostic accuracy of the
technique. Thus it is not always possible to identify the
part of the lesion with the highest Cho concentration or
reach acceptable levels of shimming due to inadequate voxel
localization. Tozaki et al. mentioned that when 1H-MRS was
applied to characterize mass lesions smaller than 15mm, the
diagnostic sensitivity in observing malignancy reached only
44%, whereas larger lesions increased diagnostic sensitivity
to 82% [2].
To the direction of accurate voxel prescription, Lenkinski
et al. mentioned that the majority of these in vivo 1H-MRS
studies have been performed using single-voxel methods,
where the lesion was ﬁrst visualized on the postcontrast
studies and the 1H-MRS voxel prescribed accordingly [8].
Those studies report that the presence of gadolinium-based
contrast agents has a minor eﬀect on the quality and peak
intensities of MR spectra. Moreover, there are few in vivo
studies determining the eﬀects of gadolinium on the 1H-
MRS on brain tumours that reported small changes (10–
15%)intheChopeakaftercontrastagentadministration[9–
14].Similarlytothosereports,Lenkinskietal.concludedthat
the negatively charged gadolinium chelates may lead to an
underestimationofthelevelsofChopresentinbreastlesions,
since most studies use postcontrast 1H-MRS as it forms
ion pairs with Cho, increasing the linewidth and dropping
signal’s height.
Therefore, as 1H-MRS is continuously being incorpo-
rated to the clinical routine, it would be of interest to study
the factors that inﬂuence the outcome of 1H-MRS and con-
sequently propose an optimized 1H-MRS procedure for in-
creased speciﬁcity in breast lesion characterization.
The present study focuses on the optimization of the 1H-
MRS procedure during clinical practice in terms of choline
detectability, pre- and postgadolinium injection.
2.Methods and Materials
2.1. Patients. Twenty four patients (Mean ± S.D.; 53 ±
12 years) with suspicious mammograms were referred for
MR evaluation. All patients were women, and none of them
was a lactating mother. Lactating breasts are metabolically
active, and there may be higher likelihood of them being
positive for 1H-MRS investigations [15, 16]. All women
underwentpre-andpostcontrast1H-MRSexaminationafter
given written informed consents. A total of 27 breast lesions
were metabolically evaluated. Pathologic correlations were
made for all patients.
2.2. MRI Acquisition. All MRI and 1H-MRS scans were
performed in the prone position for minimizing the eﬀect
of respiratory motion of the breasts, on a 3T MR scanner
(GE, Healthcare, Signa HDx), using a dedicated phased array
breast coil.
Conventional MRI protocol included axial T2-weighted
Fast Spin Echo imaging sequence (T2-FSE, TR/TE = 3,600/
100msec, slice thickness = 4mm, spacing = 0mm), axial
diﬀusion-weighted echo-planar imaging sequence (DW-EPI,
TR/TE = 6,000/minimum msec, slice thickness = 4mm,
spacing = 0mm), and axial short TI inversion recovery
imaging sequence (STIR, TR/TE = 3,875/90msec, slice
thickness = 4mm, spacing = 0mm).
Dynamic contrast enhancement MRI sequence was per-
formed using fat-suppressed three-dimensional T1-weigted
vibrant dynamic images (ﬂip angle = 10◦,1m m 3 isotropic
voxel, one unenhanced and ﬁve contrast-enhanced acquisi-
tions). Gadolinium was automatically injected over 10 sec-
onds approximately.
2.3. 1H-MRS Protocol and Spectroscopic Data Analysis.
For 1H-MRS performance a single-voxel water and fat-
suppressed point-resolved spectroscopy (PRESS) was ac-
quired before and after contrast administration for evaluat-
ing the eﬀect of neutral gadolinium chelates in MR spectra
resonances.
The hypothesis was that the postcontrast localization of
the voxel would yield a better consideration of the lesion
morphology including as much of the lesion as possible
while avoiding surrounding adipose tissue. Before 1H-MRS
was performed, the channel contralateral to the lesion was
automatically switched oﬀ. Automated parameter optimiza-
tion consisted of frequency and receiver gain adjustment
and gradient tuning. An automatic shimming adjustment
was also performed to reach a full width at half maximum
(FWHM) of the unsuppressed water peak lower than 25Hz,
as a quality parameter of the MR signal, 5Hz lower than
suggested by the manufacturer. For values greater than 25Hz
theautomatedshimmingprocedurewasrepeated.Inthecase
of a value of FWHM greater than 25Hz the voxel was re-
adjusted to the region of interest. 1H-MRS sequence was
acquired with the following technical parameters: TR/TE
= 2,000/155msec, number of excitations (NEX) = 56 for
voxel size 3.375cm3, and NEX = 32 for voxel size greater
than 3.375cm3. This relatively long TE was chosen to
increase the visibility of tCho resonance because of the
longer T2 of tCho (>350msec) in comparison to that of
lipids (∼100msec) [1] .V o x e ls i z ew a sc h o s e nn o tl e s st h a n
3.375cm3 and not greater than 8cm3, and it was carefully
adjusted to the lesion. Moreover, a strong lipid and water
spectral suppression was applied using a frequency-selective
inversion pulse surrounded by a spoiler gradient pulse of
opposite signs, which also incorporates a motion correction.
tCho resonance in breast spectra was qualitatively
determined, and the criteria for determining the presence
or absence of tCho were that a peak should be clearly
identiﬁable at 3.2ppm within the lesion.The Scientiﬁc World Journal 3
Table 1: Patient demographics, voxel size, 1H-MRS Choline presence, and histology results. Dash (—) indicates benign lesions.
Patient Age
Voxel size before
contrast
administration
(cm3)
Voxel size after
contrast
administration
(cm3)
tCho presence
before contrast
administration
tCho presence
after contrast
administration
Histopathological ﬁndings
1 33 3.375 3.375 No No —
2 50 3.375 3.375 No No —
3 74 8.000 7.500 Yes Yes Lobular adenocarcinoma
4 54 5.800 5.800 No No Invasive ductal carcinoma
5 60 8.000 8.000 Yes Yes Malignant phyllodes
yumour
6 67 8.000 8.000 No Yes Inﬁltrative lobular
adenocarcinoma
7 58 3.375 3.375 No No Grade II adenocarcinoma
8 43 4.900 4.900 No No —
9 49 3.700 3.700 Yes Yes Grade III adenocarcinoma
10 49 3.700 3.700 No Yes Grade III adenocarcinoma
11 67 3.375 3.375 No No —
12 35 3.375 4.160 Yes Yes —
13 35 3.375 4.115 Yes No —
14 35 3.375 3.375 No No —
15 52 8.000 8.000 No No —
16 47 4.500 4.500 Yes Yes Grade III adenocarcinoma
17 47 3.375 3.375 Yes Yes Grade III adenocarcinoma
18 63 6.380 3.375 Yes Yes Grade III adenocarcinoma
19 45 8.000 8.000 No No —
20 71 3.375 4.300 No Yes Lobular adenocarcinoma
21 53 6.500 6.500 No No Invasive ductal carcinoma
22 53 5.380 5.380 No No —
23 50 6.000 3.670 No No —
24 64 8.000 8.000 No No —
25 50 5.800 5.800 No No —
26 37 3.375 6.500 No Yes Inﬁltrative adenocarcinoma
27 52 3.375 3.700 No Yes Grade III adenocarcinoma
Table 2: Measures of overall accuracy, sensitivity, and speciﬁcity using tCho presence in discrimination of benign from malignant breast
lesions.
tCho presence (%) Accuracy (%) Sensitivity (%) Speciﬁcity
Before contrast injection 62.9 42.8 84.6
After contrast injection 85.1 78.5 92
3. Results
Table 1 summarizes the patient demographics, voxel size,
and tCho presence or absence before and after contrast
administration as well as histopathologic ﬁndings.
1H-MRS ﬁndings before contrast injection indicated
that 6/14 conﬁrmed malignancies and 11/13 benign lesions
were correctly diagnosed (accuracy 62.9%, sensitivity 42.8%,
and speciﬁcity 84.6%), whereas spectroscopy after contrast
injection indicated 11/14 conﬁrmed malignancies and 12/13
benign processes (accuracy 85.1%, sensitivity 78.5%, and
speciﬁcity 92%). Accuracy, sensitivity, and speciﬁcity results
are summarized at Table 2.
The eﬀects of gadolinium chelates on tCho resonance
after contrast administration are shown in Figures 1 and
2. Figure 1 corresponds to an MRS evaluation in a sizeable
malignant lesion while keeping the same size and position of
the voxel before and after contrast injection. In this case, the
administration of contrast caused mild-line broadening and
decreased tCho peak’s height without impeding malignancy
assessment. This probably is a result of the direct contact
of tCho with the contrast agent in order to form a4 The Scientiﬁc World Journal
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Figure 1: Breast MR spectra of a 60-year old patient, before (a) and 8min after (b) contrast injection using a voxel of 14.7∗16.8∗15cm3.
The relative tCho peak intensity decreases, and line-width broadening in the postcontrast spectra is clearly visible.
complex, which leads to shortening of the relaxation times
of the methyl protons of tCho through the electron-dipole
interaction.
On the contrary, when readjusted, the voxel in a smaller
lesion, following the postcontrast image of the lesion, the
line broadening, and the tCho peak’s height, was further
improved as suggestively is illustrated in Figure 2.H e n c ei t
is evident that, after contrast administration, a more adapted
andaccuratevoxellocalizationuponthebreastlesionderived
better results.
Similarly, Figure 3 illustrates a case of a malignant breast
lesion in which the selected voxel size of 15∗15∗15cm3
before gadolinium injection did not adequately detect the
tCho peak, and the lesion was misinterpreted as benign.
However, after contrast administration, the lesion’s delin-
eation allowed a more accurate voxel prescription. The
sensitivityofpickingupadequatetChosignalfromthelesion
increased, as surrounded adipose tissue was avoided, and
it is correctly diagnosed as malignant. This result was later
histologically veriﬁed.
When adipose tissue that is not part of the pathologic
process in breast cancer is included in the voxel for 1H-MRS,
it reduces localized shimming, as its magnetic susceptibility
diﬀers from that of malignant tissues. In addition, the
interaction between lipid signals and the pulsed gradients
necessary for localization may produce lipid sideband arti-
facts, consequently causing spectral artifacts which may
hinder interpretation of tCho signal [17]. As also shown
in Figure 4, shimming signiﬁcantly improved after contrast
injection from 25 to 12Hz. In that case, with the reduction
of voxel size, the region of interest included greater amount
of lesion than surrounding breast parenchyma; thus, ﬁeld
homogeneity allowed higher spectral resolution.
The aforementioned results recommend that 1H-MRS
accuracy, sensitivity, and speciﬁcity in detecting tCho reso-
nance and hence lesion’s malignancy are increased acquiring
postcontrast spectra. The suggested reason for this improve-
ment is the optimized lesion localization, resulting in better
voxel positioning, exclusion of signiﬁcant residual tissue
signal, and thus increase of the signal-to-noise ratio of tCho
signal and improvement of ﬁeld homogeneity inside the
region of interest.
In order to characterize breast masses larger than
3.375cm3 where a voxel of 1.5∗1.5∗1.5cm3 or bigger canThe Scientiﬁc World Journal 5
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Figure 2: Breast MR spectra of a 49-year old patient, before (a) and 8min after (b) contrast injection using a voxel of 20∗20∗20cm3.T h e
relative tCho peak intensity increase and line-width narrowing in the postcontrast spectra is clearly visible after better readjustment of the
voxel on the lesion.
provide full lesion coverage, as that depicted in Figure 1,
it is more prudent to perform 1H-MRS before contrast
injection to allow the diagnostic resonance to be recorded,
while maintaining the highest possible spectral resolution.
However, when lesions are smaller or nonmass without
clearly identiﬁable margins, it is recommended to perform
1H-MRS after contrast injection for better voxel prescription
to enable an accurate and reliable preoperative diagnosis of
such breast lesions (Figures 3 and 4).
4. Discussion
As a biochemical measure of metabolism, 1H-MRS can
detect cellular membrane turnover and proliferation by
monitoring levels of a collection of chemicals with a choline
base [18]. Elevated levels of the composite Cho signal (tCho)
have been reported in many studies of excised human breast
tumours, cultured human breast cancer cells, and animal
models [16]. Fewer studies though have been devoted to the
performance of in vivo 1H-MR spectroscopic detection of
tCho in breast lesions [1–3, 10].
In this study, the eﬀectiveness of clinical pre- and
postcontrast 1H-MR spectroscopy in distinguishing between
benign and malignant breast lesions at 3T was examined,
andanoptimized1H-MRSprocedureforincreasedaccuracy,
sensitivity, and speciﬁcity of detecting breast lesion malig-
nancy was proposed.
Several parameters set during an automated 1H-MRS
prescan procedure aﬀect the eﬀectiveness of the technique
and typically include shimming, radiofrequency (RF) power
calibrations, frequency adjustment, and voxel localization
performance.
Although all the prescan adjustments are important
in the acquisition of high-quality in vivo MRS data, two
parameters hold particular importance (shimming and voxel
prescription), and thus it is crucial to spend the necessary
time to achieve a well-shimmed region of interest (ROI),
good water suppression, and thus high resolved spectra [19].
Variations in the main magnetic ﬁeld (B0) that arise
from extrinsic factors (notably susceptibility-induced ﬁeld
shifts) cause broadened and distorted peaks and must
be minimized in order to acquire high-quality in vivo
MRS data. Susceptibility-induced magnetic ﬁeld distortions6 The Scientiﬁc World Journal
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Figure 3: Breast MR spectra of a 35-year old patient with malignant breast lesion, before contrast injection (a) using a voxel of
15∗15∗15cm3 and 8min after (b) contrast injection using a voxel of 17∗16.3∗15cm3 which is more adapted to the lesion’s size. After
contrast injection, tCho peak is clearly detectable.
primarily arise from the diﬀerent magnetic permeabilities.
Consequently, when a subject is in a MR scanner, signiﬁcant
B0 inhomogeneities are generated that depend on the
presence and distribution of diﬀerent tissue types. These
B0 inhomogeneities are often the dominant factor limiting
successful MRS applications.
T h ec h o i c eo fv o x e lp o s i t i o na n ds i z ei sc r i t i c a lt o
achieve a good-quality diagnostic spectrum. Obviously it
is important to locate the voxel in the appropriate area
to detect the pathology under investigation. For example,
within a breastlesion, there may be neoplastic, ﬁbrogranular,
or adipose tissue obscuring the choline resonance.
Additionally, high-quality MR images are needed for
accurate voxel prescription. In order to characterize a breast
lesion, the voxel should be in the active tumour, but it can
be diﬃcult to distinguish these regions especially when the
lesion is small or nonmass. As conﬁrmed by this study,
gadolinium has only a small eﬀect on Cho peak (causing a
small amount of line broadening), so postcontrast scans can
be useful. As shown in Figures 2 and 3, after correction of
voxel adjustment upon the breast lesion, the relative Cho
peak intensity increased and linewidth became narrower in
the postcontrast spectra.
The fact that the linewidth of the residual Cho resonance
in the presence of neutral gadolinium chelates increased
(Figure 1) and the intensity of the tCho peak decreased,
while maintaining voxel’s size ﬁxed, indicates that the area
under the tCho curve remains unchangeable. As Lekinski et
al. mentioned, these observations can only be explained by
direct interactions of Cho with contrast agent rather than
through any bulk susceptibility eﬀects [8]. Whatever the
explanation for the decrease in the levels of Cho that we
observed, keeping the voxel ﬁxed at pre- and postcontrast
1H-MRS, it seems that the gadolinium chelates may lead
to a misinterpretation of the Cho present in human breast
lesions. It is therefore advisable that if breast lesion is large
enough to allow full coverage of a 3.375cm3 voxel, then it
is prudent to perform 1H-MRS before contrast injection, to
avoid signal perturbation and choline underestimation.
Our recommendation is also veriﬁed by the study of
Baltzer et al. who reported that interaction of the contrast
agent with Cho can cause false negative ﬁndings, especiallyThe Scientiﬁc World Journal 7
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Figure 4: Breast MR spectra of a 63-years old patient with malignant breast lesion, before contrast injection (a) using a voxel of
18∗19.7∗18cm3 and 8min after (b) contrast injection using a voxel of 15∗15 ∗15cm3 which is more adapted to the lesion’s size. After
contrast injection the overall spectral resolution is better as FWHM has reduced from 25Hz to12Hz.
in cases when signal-to-noise ratio of tCho is limited [20].
Therefore, they suggest that when Cho peak is clearly visible
v i ap r e c o n t r a s t1 H - M R S ,i ti sr e c o m m e n d e dt h a ti ti sm o r e
prudent to measure Cho SNR from precontrast spectra for
avoiding signal misinterpretation and Cho concentration
underestimation in cases of absolute quantiﬁcation.
On the other hand, during voxel prescription for 1H-
MR spectroscopy, care should be taken to include as much
of the lesion as possible while avoiding surrounding adipose
tissue. In this study it was veriﬁed that before contrast
administration, breast lesion margins are often not clearly
identiﬁed especially in dense breast parenchyma. Therefore,
the voxel size could be selected quite large or eccentric
in respect to lesion size and location, respectively; hence
Cho could become undetectable. To avoid false-negativity
in the characterization of breast lesions, it is important to
localize the voxel after contrast injection, for accurate voxel
assessment. As illustrated in Figure 2, it is suggested that,
after contrast administration, the more careful consideration
of lesion morphology and enhancement kinetics allowed
more accurate voxel localization upon the breast lesion. This
derived less ﬁeld inhomogeneity inside the selected voxel
(Figure 4) resulting in high-quality spectra and thus higher
overall accuracy, sensitivity, and sensitivity in detecting
lesion’s malignancy. Taking into account that the presence of
gadolinium itself does not signiﬁcantly aﬀect the Cho signal,
our ﬁndings are in agreement with studies supporting that
the lesional size is one of the main issues which must be
ensured in the performance of clinical in vivo breast 1H-
MRSforpickingupadequateamountoftChosignal[16,17].8 The Scientiﬁc World Journal
Thus, the likelihood to diﬀerentiate between malignant and
benign breast lesions is increased using postcontrast 1H-
MRS techniques.
Furthermore, variations in the main magnetic ﬁeld (B0)
that arise from diﬀerent magnetic permeability of fat and
lesion tissue interface cause broadening and distortion of
spectrum resonance characteristics and must be minimized
to acquire high-quality in vivo MR spectra [17]. The
aforementioned observations are also conﬁrmed from the
p r e s e n ts t u d y ,w i t hi m p r o v e do v e r a l la c c u r a c y ,s e n s i t i v i t y ,
and speciﬁcity of 1H-MRS technique in detecting lesion’s
malignancy after contrast agent administration as the region
of interest was more accurately deﬁned. Thus, it is suggested
that, in order to exclude signiﬁcant fatty tissue signal
contribution in the assessed volume of interest, 1H-MRS
should be performed after gadolinium injection. Exclusion
of adipose tissue from the voxel lead is to correct tCho
sampling of the lesion and derives better shimming results
and better spectral resolution, as depicted in ﬁgures 3 and 4,
respectively, in concordance with Yeh [21].
Considering that the 1H-MRS signal is an average of
multiple signals acquired in possibly diﬀerent breathing
phases, without a frequency correction, both the peak
position and height, as well as the peak SNR are infected.
Therefore, any improvement in the signal-to-noise ratio that
will eﬀectively enhance the detection of tCho signal may
further increase the speciﬁcity and sensitivity, improving the
diagnostic performance of breast 1H-MRS [17, 21].
5. Conclusion
1H-MRS can be very useful in the detection and diﬀer-
entiation of malignant from nonmalignant breast lesions
and can be implemented as an invaluable tool in the
clinical setting. Furthermore our results recommend that
1H-MRS accuracy, sensitivity, and speciﬁcity in detecting
tCho resonance and hence lesion’s malignancy of breast
lesions are increased when acquiring postcontrast spectra.
The suggested reason for this improvement is the increase of
the signal-to-noise ratio of tCho signal and the improvement
of ﬁeld homogeneity inside the region of interest, which is
caused by the optimized voxel positioning on the lesion,
resulting in the exclusion of signiﬁcant residual tissue signal
contribution in the assessed volume of interest.
However, gadolinium-based contrast agents can have
f r o mm i n o rt os tr o n g e re ﬀects on tCho detection in postcon-
trast 1H-MRS. It is therefore advisable that if breast lesion is
large enough to allow accurate detection and full coverage of
a >3.375cm3 voxel (15 × 15 × 15mm3), then it is prudent to
perform 1H-MRS before contrast injection, to avoid signal
perturbation and choline underestimation. On the other
hand in cases of small or not well-oriented lesions, it is
recommended to perform 1H-MRS after contrast injection
for better voxel prescription to enable an accurate and
reliable preoperative diagnosis.
We strongly recommend that, in any 1H-MRS experi-
ment, the MR acquisition parameters should be adjusted on
a case dependent basis in order to obtain optimum spectral
resolution and Cho SNR.
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